These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 85826)

  • 1. Provision of medicines in a developing country.
    Yudkin JS
    Lancet; 1978 Apr; 1(8068):810-2. PubMed ID: 85826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug control: a prerequisite for health.
    Yudkin JS
    Proc R Soc Lond B Biol Sci; 1980 Jul; 209(1174):159-63. PubMed ID: 6106937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When medicine becomes a disease.
    Arabia; 1986 Mar; 5(55):32-6. PubMed ID: 12340711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The multinational drug companies in Zaire: their adverse effect on cost and availability of essential drugs.
    Glucksberg H; Singer J
    Int J Health Serv; 1982; 12(3):381-7. PubMed ID: 7118328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.
    Maniadakis N; Kourlaba G; Shen J; Holtorf A
    BMC Health Serv Res; 2017 May; 17(1):371. PubMed ID: 28545440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of pharmaceutical supply in Tanzania.
    Yudkin JS
    Int J Health Serv; 1980; 10(3):455-77. PubMed ID: 7419314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug discovery and developments in developing countries: bottlenecks and way forward.
    Nyigo VA; Malebo HM
    Tanzan Health Res Bull; 2005 Sep; 7(3):154-8. PubMed ID: 16941941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of essential drug programmes.
    Smith GT
    Soc Sci Med; 1987; 25(6):621-4. PubMed ID: 3686096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 10. Sparks fly over patents and vital drugs at world health assembly.
    Kapp C
    Lancet; 2003 May; 361(9372):1873. PubMed ID: 12788578
    [No Abstract]   [Full Text] [Related]  

  • 11. Economics of essential drugs schemes: the perspectives of the developing countries.
    Wang'ombe JK; Mwabu GM
    Soc Sci Med; 1987; 25(6):625-30. PubMed ID: 3686097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
    Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
    Theriaca; 2016; (43):9-61. PubMed ID: 27491172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of pharmaceuticals in the total health care of developing countries.
    Hoekenga MT
    Am J Trop Med Hyg; 1983 May; 32(3):437-46. PubMed ID: 6859394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [On misery coast. Episode 1: the market of vital drugs].
    Chneiweiss H
    Med Sci (Paris); 2003; 19(8-9):892-4. PubMed ID: 14593623
    [No Abstract]   [Full Text] [Related]  

  • 15. Medicines for the world: a way forward.
    James JS
    AIDS Treat News; 2004 Mar; (399):7-8. PubMed ID: 15199870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
    Burci GL; Gostin LO
    JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
    [No Abstract]   [Full Text] [Related]  

  • 17. Public drug procurement: the lessons from a drug tender in a teaching hospital of a transition country.
    Milovanovic DR; Pavlovic R; Folic M; Jankovic SM
    Eur J Clin Pharmacol; 2004 May; 60(3):149-53. PubMed ID: 15057496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring the impact of clawback on pharmaceutical expenditure: A case study of public hospitals in Greece.
    Letsios AN; Mavridoglou G; Ladopoulou D; Tsourdini D; Dedes N; Polyzos NM
    Int J Health Plann Manage; 2023 Sep; 38(5):1539-1554. PubMed ID: 37477549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for the poor of the Third World: consumption and distribution.
    Mills A; Walker GJ
    J Trop Med Hyg; 1983 Aug; 86(4):139-45. PubMed ID: 6668634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.